Clinical Trials Logo

Refractory Shock clinical trials

View clinical trials related to Refractory Shock.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04339868 Recruiting - Septic Shock Clinical Trials

Terlipressin for Refractory Septic Shock

TERESEP
Start date: April 3, 2020
Phase: Phase 2
Study type: Interventional

Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended. Vasopressin was also recommended as an alternative vasopressor, in case patient did not response to norepinephrine and or epinephrine. Terlipressin, a selective V1 receptor binding with long half life, was reported that it main action is to increase blood pressure via the different mechanism from norepinephrine and epinephrine. To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the side effects of too high adrenergic stimuli.

NCT ID: NCT04110418 Recruiting - Neonatal Sepsis Clinical Trials

Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate

Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

A randomized, prospective study comparing methylene blue versus terlipressin in treatment of catecholamines resistant shock in preterm neonate

NCT ID: NCT03038503 Recruiting - Septic Shock Clinical Trials

What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6 hours of resuscitation, the goals of resuscitation in sepsis shock after adequate fluid resuscitation is MAP ≥65 mmHg. In refractory septic shock patient, prolong shock correlate with poor outcome due to multiple organ failure. Alternative vasopressor in septic shock with catecholamine resistance has been studied such as terlipressin, methylene blue - Terlipressin (TP) mediate vasoconstriction via V1 receptors coupled to phospholipase C, and increases intracellular Ca2+ concentration - Methylene blue (MB) directly inhibits nitric oxide synthase (NOS) by inhibit the enzyme guanylate cyclase (GC)